<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697707</url>
  </required_header>
  <id_info>
    <org_study_id>DCOne-002</org_study_id>
    <nct_id>NCT03697707</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia</brief_title>
  <acronym>ADVANCE-II</acronym>
  <official_title>An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DCPrime BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DCPrime BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and&#xD;
      with presence of MRD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      International, multicentre, open-label proof of concept study exploring two different dose&#xD;
      groups of the allogeneic dendritic cell vaccine, DCP-001. Cohort 1 consists of 10 patients&#xD;
      that will receive 25E6 DCP-001 cells per vaccination and Cohort 2 consists of 10 patients who&#xD;
      will receive 50E6 DCP-001 cells per vaccination. All patients will be given two additional&#xD;
      booster vaccinations of 10E6 cells. Each patient will be followed up for 12 months after the&#xD;
      4th vaccination. Safety will be monitored throughout the study. Sera and cell samples (blood&#xD;
      and bone marrow) will be collected for assessment of efficacy (MRD evaluation) and immune&#xD;
      response monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>First 10 patients will get the lowest dose and next 10 patients will receive the highest dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>minimal residual disease (MRD)</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Any change in MRD (flow cytometric) as compared to baseline MRD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events (TEAEs)</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune responses</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Any change in immunoreactivity (specific and non-specific) as compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCP-001</intervention_name>
    <description>allogeneic dendritic cell vaccine</description>
    <arm_group_label>Cohort 1: Low dose</arm_group_label>
    <arm_group_label>Cohort 2: High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of AML according to WHO2016 criteria, including cytological,&#xD;
             molecular and cytogenetic criteria (except acute pro-myelocytic leukaemia/APL).&#xD;
&#xD;
          2. In CR1 (first complete remission) or CRi (incomplete blood count recovery) documented&#xD;
             by bone marrow examination up to one month before vaccination; CR defined as less than&#xD;
             5% blasts in normo-cellular bone marrow, ANC &gt;1*E9/L, platelet count &gt;100*E9/L, no&#xD;
             evidence of extra-medullary disease. Patients in CRi (patients with &lt;5% blasts but&#xD;
             with incomplete blood count recovery) should have platelets &gt;50 E9/L.&#xD;
&#xD;
          3. MRD as defined by multicolour flow cytometry (MFC) at a value of &gt; 0.1%, or detection&#xD;
             of specific molecular abnormalities such as NPM1 mutation.&#xD;
&#xD;
          4. Patients that are in CR1 or CRi. Patients not having undergone consolidation therapy&#xD;
             must have been in CR1 for at least 1 month prior to enrolment. Patients treated with&#xD;
             hypomethylating agents must have been given at least two cycles and up to a maximum of&#xD;
             nine cycles of hypomethylating agents.&#xD;
&#xD;
          5. Expected and willing to undergo all study procedures, including outpatient evaluations&#xD;
             for clinical and immunological monitoring.&#xD;
&#xD;
          6. Male or female of ≥ 18 years of age.&#xD;
&#xD;
          7. Women of childbearing potential must be using anti-conceptive therapy or use two (2)&#xD;
             barrier contraceptive methods (one by each partner and at least one of the barrier&#xD;
             methods must include spermicide (unless spermicide is not approved in the country or&#xD;
             region). See section 12.7 for birth control methods deemed acceptable for this study.&#xD;
&#xD;
          8. ECOG (WHO) performance status 0-2.&#xD;
&#xD;
          9. Willing and able to provide written informed consent for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute Promyelocytic (APL; M3) type of AML.&#xD;
&#xD;
          2. Patients who have undergone or are scheduled/eligible for allogeneic stem cell&#xD;
             transplantation.&#xD;
&#xD;
          3. History of previous allogeneic bone marrow or solid organ transplantation.&#xD;
&#xD;
          4. Uncontrolled or serious infections&#xD;
&#xD;
          5. Ongoing immunosuppressive therapy, other than short use of low dose steroids, i.e.&#xD;
             equivalent to an average dose of ≤10mg of prednisone/day.&#xD;
&#xD;
          6. Chemotherapy and antineoplastic hormonal therapy within 28 days prior to the screening&#xD;
             visit, with the exception of hypomethylating agents such as azacitidine and&#xD;
             decitabine, or midostaurin for FLT3 mutations, or patients treated with IDH12&#xD;
             inhibitors in mIDH1/2.&#xD;
&#xD;
          7. Current or past medical history autoimmune disease.&#xD;
&#xD;
          8. Inadequate liver function (AST and ALT &gt; 3 x ULN, serum bilirubin &gt;3 x ULN).&#xD;
&#xD;
          9. Other active Malignancies within the last 5 years, except for adequately treated&#xD;
             carcinoma in situ of the cervix or squamous carcinoma of the skin or adequately&#xD;
             controlled limited basal cell skin cancer.&#xD;
&#xD;
         10. Pregnant or lactating females.&#xD;
&#xD;
         11. Major surgical procedure (including open biopsy) within 28 days prior to the first&#xD;
             study treatment, or anticipation of the need for major surgery during the course of&#xD;
             the study treatment.&#xD;
&#xD;
         12. Uncontrolled hypertension (systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg) or&#xD;
             clinically significant (i.e. active) cardiovascular disease.&#xD;
&#xD;
         13. Evidence of any other medical conditions (such as psychiatric illness, physical&#xD;
             examination or laboratory findings) that may interfere with the planned treatment,&#xD;
             affect patient compliance or place the patient at high risk from treatment-related&#xD;
             complications.&#xD;
&#xD;
         14. Known HIV, Hepatitis B and/or Hepatitis C infections.&#xD;
&#xD;
         15. History of hypersensitivity to the investigational medicinal product or to any&#xD;
             excipient present in the pharmaceutical form of the investigational medicinal product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A A van de Loosdrecht, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats Klinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital</name>
      <address>
        <city>Düsseldorf</city>
        <zip>D- 40479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats Klinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland universitetssjukehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.</citation>
    <PMID>30039426</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML in CR1 or CRi</keyword>
  <keyword>DCOne</keyword>
  <keyword>DCP-001</keyword>
  <keyword>Minimal Residual Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

